Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBITDA Margin (2016 - 2025)

Agios Pharmaceuticals' EBITDA Margin history spans 13 years, with the latest figure at 608.89% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 55641.0% year-over-year to 608.89%; the TTM value through Dec 2025 reached 873.87%, up 29260.0%, while the annual FY2025 figure was 873.87%, 29260.0% up from the prior year.
  • EBITDA Margin reached 608.89% in Q4 2025 per AGIO's latest filing, up from 907.37% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 608.89% in Q4 2025 to a low of 12156.85% in Q1 2022.
  • Average EBITDA Margin over 4 years is 2068.27%, with a median of 1295.97% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: soared 1054136bps in 2023, then plummeted -9763bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 2300.97% in 2022, then surged by 35bps to 1496.23% in 2023, then grew by 22bps to 1165.3% in 2024, then soared by 48bps to 608.89% in 2025.
  • Per Business Quant, the three most recent readings for AGIO's EBITDA Margin are 608.89% (Q4 2025), 907.37% (Q3 2025), and 1020.12% (Q2 2025).